HLF1-11
Based on 1 Customer Validation
HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses.
For research use only. We do not sell to patients.
- Purity : 99.73%
- CAS No.: 183623-03-2
- Formula: C56H95N25O14S
- Molecular Weight:1374.58
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Biological Activity
Description
In Vitro
hLF1-11 (1, 10, and 100 μg/mL) directs differentiation of monocytes toward a macrophage subset during granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven monocytes differentiation[2].
hLF1-11 (0.5-250 μg/mL) inhibits human MPO activity[3].
hLF1-11 (100 μg/mL, 90 min) inhibits ROS induction induced by LPS in monocytes[3].
hLF1-11 (8-34 μΜ, 2 h) is active against fluconazole-resistant C. albicans[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
hLF1-11 (40 μg/kg, i.v.) is active against C. albicans-infected mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rabbits inoculated with CFU MRSA[4]
-
Dosage:20 mg/kg
-
Administration:Injected into the debrided tibial cavity
-
Result:Reduced bacterial load compared to controls, and reduced the radiological and histopathological score.
-
Animal Model:Neutropenic mice challenged i.v. with C. albicans
-
Dosage:40 μg/kg
-
Administration:Intravenous injection (i.v)
-
Result:Reduced serum TNFα and IL-6 in infected mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 183623-03-2
-
Appearance Solid
-
Molecular Weight 1374.58
-
Formula C56H95N25O14S
-
Color White to off-white
-
Sequence Shortening
GRRRRSVQWCA
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (72.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (72.75 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
THP-1 Cell Differentation
Macrophages are important immune effector cells and play an important role in innate and adaptive immune responses. THP-1 cells are usually induced to differentiate into macrophages with PMA.
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[2]. van der Does AM, et al. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother. 2010 Feb;54(2):811-6. [Content Brief]
[3]. van der Does AM, et al. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J Immunol. 2012 May 15;188(10):5012-9. [Content Brief]
[4]. Faber C, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother. 2005 Jun;49(6):2438-44. [Content Brief]
[5]. Lupetti A, et al. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother. 2000 Dec;44(12):3257-63. [Content Brief]
[6]. upetti A, et al. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis. 2007 Nov 1;196(9):1416-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 0.7275 mL | 3.6375 mL | 7.2749 mL | 18.1874 mL |
| 5 mM | 0.1455 mL | 0.7275 mL | 1.4550 mL | 3.6375 mL | |
| 10 mM | 0.0727 mL | 0.3637 mL | 0.7275 mL | 1.8187 mL | |
| 15 mM | 0.0485 mL | 0.2425 mL | 0.4850 mL | 1.2125 mL | |
| 20 mM | 0.0364 mL | 0.1819 mL | 0.3637 mL | 0.9094 mL | |
| 25 mM | 0.0291 mL | 0.1455 mL | 0.2910 mL | 0.7275 mL | |
| 30 mM | 0.0242 mL | 0.1212 mL | 0.2425 mL | 0.6062 mL | |
| 40 mM | 0.0182 mL | 0.0909 mL | 0.1819 mL | 0.4547 mL | |
| 50 mM | 0.0145 mL | 0.0727 mL | 0.1455 mL | 0.3637 mL | |
| 60 mM | 0.0121 mL | 0.0606 mL | 0.1212 mL | 0.3031 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.